NCT03932513View on ClinicalTrials.gov

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

December 21, 2019

Study Completion Date

December 21, 2019

Conditions
HBVHepatitis BHepatitis B, Chronic
Interventions
DRUG

inarigivir soproxil

Inarigivir 200mg and 400mg oral tablets, once daily

Trial Locations (1)

Unknown

National University Hospital, Singapore

Sponsors
All Listed Sponsors
collaborator

CSI Medical Research Pte Ltd

UNKNOWN

lead

F-star Therapeutics, Inc.

INDUSTRY